The Acne Bacterium Is Missing From This Anti-Acne Cream Study

On August 11, 2026, the journal Clinical, Cosmetic and Investigational Dermatology published a preclinical study of a topical cream made from the stem bark of Psorospermum febrifugum, a small tree in the Hypericaceae family, the same family as St. John's wort, used across East and West Africa for skin sores, scabies and fevers. The researchers, working with ethics approvals from Maseno University in Kenya and Makerere University in Uganda, and an animal facility at King Ceasor University in Kampala, formulated a standardized bark extract into a cream at concentrations of one to five percent and tested whether it could interrupt one of acne's chemical pathways: the breakdown of sebum into the free fatty acids that irritate skin and help form comedones.

The paper's title is precise about what it covers: lipase inhibition, sebum regulation, dermal safety. It delivers data on all three. What does not appear anywhere in its methods is a test of the finished cream against Cutibacterium acnes, the bacterium whose name sits inside the condition the cream is meant to treat.

The enzyme it tested is not the bacterium's own

The lipase-inhibition experiment used porcine pancreatic lipase, a digestive enzyme purified from pig pancreas and sold for laboratory use, with orlistat (the anti-obesity drug that works by blocking that same enzyme in the human gut) as the benchmark. The extract-loaded cream at five percent produced 57.0 percent inhibition of this enzyme, with a half-maximal inhibitory concentration of 0.84 mg/mL; orlistat itself reached 88.1 percent inhibition at 0.62 mg/mL. Those are real, dose-dependent numbers, and the authors report them plainly.

They also report, in their own limitations section, why the choice of enzyme matters:

the enzyme differs structurally and kinetically from Cutibacterium acnes lipase

Pig pancreatic lipase is a standard, inexpensive stand-in used across botanical screening because it is commercially available and easy to assay; the C. acnes enzyme actually implicated in acne, a secreted lipase called GehA, is harder to produce and rarely used in this kind of first-pass test. That substitution is common practice, not a flaw unique to this paper, and the authors flag it rather than hide it. But it means the enzyme result speaks to a lipase found in a pig's digestive tract, not the one the target bacterium secretes onto human skin.

What the sebum test showed, in rats

The second arm was an in vivo model: adult Wistar rats had seborrhea induced on shaved dorsal skin with daily applications of ten percent oleic acid for seven days, then received fourteen days of once-daily cream treatment while sebum output was measured with absorbent Sebutape strips. By day fourteen, the five percent cream reduced sebum by 60.7 percent, close to the 62.3 percent reduction from a benzoyl peroxide comparator, and the paper reports a strong correlation between lipase inhibition in the enzyme assay and sebum reduction in the animals (Pearson r = 0.88, p < 0.01). That correlation is a useful internal consistency check. It is not evidence that the cream acts on skin bacteria, only that whatever it is doing to reduce measured oil output tracks with what it does to the pancreatic enzyme in a test tube.

A safety result drawn from a shorter exposure than the efficacy claim

The dermal safety data came from a separate cohort of rats under OECD Test Guideline 404, the standard acute dermal irritation protocol: a single application to a small shaved patch, covered for four hours, scored for erythema and swelling at 24, 48 and 72 hours afterward. The extract creams scored under 0.2 on the Draize irritation index, classed as non-irritant; the benzoyl peroxide comparator scored 0.85, mildly irritant. That is a genuinely favorable early signal, and it matters, since irritation is a common reason people abandon topical acne treatments. But it is worth noting what the guideline measures: a single four-hour exposure, not the fourteen days of daily application used in the efficacy arm. Nothing in the paper reports skin response after two straight weeks of the cream, only after one four-hour patch.

The bacterium the study never met

Acne's standard clinical picture involves three linked factors: excess sebum, blocked follicles, and colonization by C. acnes that triggers inflammation. This paper addresses only the first of those directly, and does so with a proxy enzyme rather than the bacterium's own. Nowhere in its methods, results or phytochemical analysis does the cream get tested against the organism itself, whether by disk diffusion, minimum inhibitory concentration, or any other standard microbiology assay.

That gap is worth naming because the plant has, in fact, been tested against C. acnes before, just not in this cream, and not by this team. A 2016 study of Psorospermum febrifugum found that a raw stem bark extract inhibited C. acnes at a minimum inhibitory concentration of 12.5 mg/mL, four times more potent than the leaf extract from the same plant. That result exists in the literature. It simply was not repeated here, on the formulated product that is now the subject of a peer-reviewed cream study carrying the words "anti-acne" in its title.

What a reader can carry forward

What the new paper establishes: a standardized bark extract, formulated as a cream, measurably inhibits a surrogate digestive enzyme in a dose-dependent way; it reduces induced sebum output in rats over two weeks at a rate comparable to a common acne drug; and it produced no irritation on rat skin after a single four-hour exposure. Those are documented, dated findings from a named journal, with numbers attached.

What remains open is just as specific:

• Whether the finished cream, not just the raw extract in an older paper, has any direct effect on C. acnes itself
• Whether a pig pancreatic enzyme predicts anything about the bacterium's own secreted lipase, GehA, which the authors acknowledge is structurally different
• Whether skin tolerates the cream after fourteen days of daily use the way it tolerated one four-hour patch
• Whether sebum reduction in rat skin translates to human sebaceous glands, which the paper does not claim to test

None of that makes the study worthless; preclinical work is supposed to be narrow, and this one says so about its own limits more candidly than most wire summaries do. But a reader deciding how much weight to put on an "anti-acne" headline has a fair question to bring to it, or to a dermatologist: does this claim rest on a test of the bacterium, or on a marker that moves alongside it? For this particular cream, on this particular date, the honest answer is the second one.

Sources: OECD Test No. 404: Acute Dermal Irritation/Corrosion · The Scientific World Journal, via PMC